Lipocine’s 30% Surge After Canadian TLANDO Approval Puts Regulatory Catalysts in Focus
Lipocine’s LPCN shares rose 30% after Health Canada approved TLANDO, expanding the drug’s cross-border commercial opportunity.
Viatris-Pacira $36.50 Cash Deal Puts Merger-Arbitrage Focus on VTRS and PCRX
Viatris’s $36.50-per-share cash agreement to acquire Pacira puts PCRX’s deal spread and VTRS’s balance-sheet flexibility in focus.
Trade with the conviction of the 1%.
Institutional-grade market intelligence delivered before the opening bell.
Lipocine Shares Jump 30% After Health Canada Approves TLANDO Testosterone Therapy
Lipocine shares surged 30% after Health Canada approved TLANDO, expanding the oral testosterone therapy’s availability i…
ArriVent BioPharma Plunges 47% After Phase III Lung Cancer Trial Miss
ArriVent’s $AVBP stock fell 46.98% after its FURVENT Phase III trial missed its primary endpoint, cutting market value t…
Viatris’ $36.50-a-Share Pacira Deal Signals Fresh Consolidation in Specialty Pharma
Viatris’ all-cash Pacira acquisition highlights continued US pharmaceutical consolidation and puts specialty-pharma valu…
SeaStar Medical’s FDA Breakthrough Designation Puts $ICU on the Investor Watchlist
SeaStar Medical’s FDA Breakthrough Device designation for its sepsis-therapy device could sharpen investor attention, bu…
Vaxcyte Stock Jumps 30.7% After Positive VAX-31 Pneumococcal Vaccine Data
Vaxcyte shares surged 30.70% after positive Phase 2 data for VAX-31, highlighting the volatility of clinical-stage biote…
Amgen Price Target Raised to $380 as Sjögren’s Trial Strengthens Pipeline Case
Truist raised Amgen’s target to $380 after positive Phase 3 dazodalibep results strengthened the company’s pipeline narr…
BridgeBio Maintains Buy Rating After Cardiac Data From Phase 3 FORTIFY Study
Canaccord reiterated its Buy rating on BridgeBio Pharma after exploratory cardiac data from the Phase 3 FORTIFY study of…
AbbVie Adds Two FDA Breakthrough Designations as Temab-A Builds Pipeline Momentum
AbbVie’s Temab-A earned two FDA breakthrough designations, adding an oncology catalyst alongside JUVMO approval and broa…
Lipocine Stock Jumps 30% on Health Canada Approval for TLANDO
LPCN’s 30% jump adds regulatory, commercial and clinical catalysts to a biotech trading setup focused on potential follo…